Latest On China Pharma Holdings, Inc (CPHI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-02-25 05:15 EST | News | China Pharma launches 1-for-10 reverse stock split | N/A |  |
| 2022-12-05 23:49 EST | News | China Pharma more than doubles on acquisition of dry eye disease therapeutic device project | N/A | |
| 2022-10-03 09:50 EST | News | China Pharma gets NYSE American listing deficiency notice | N/A | |
| 2022-07-19 01:41 EST | News | China Pharma files plan of compliance to NYSE American | N/A | |
| 2022-06-22 17:37 EST | News | China Pharma receives non-compliance letter from NYSE American | N/A | |
| 2022-04-01 04:34 EST | News | China Pharma GAAP EPS of -$0.07, revenue of $9.6M | N/A | |
| 2021-03-30 04:05 EST | News | Despite audit finding 'substantial doubt' about future, China Pharma shares soar 43% (updated) | N/A | |
| 2021-03-27 19:30 EST | News | Audit finds 'substantial doubt' about China Pharma's future; shares plummet 43% | N/A | |
| 2020-12-13 03:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 11:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 00:04 EST | News | China Pharma reports Q3 results | N/A | |
| 2020-11-07 15:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-06 00:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-16 08:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 16:00 EST | News | China Pharma reports Q2 results | N/A | |
| 2020-07-31 00:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-10 08:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-31 16:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-20 12:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-18 06:43 EST | News | China Pharma reports Q1 results | N/A | |
| 2020-05-03 08:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 20:15 EST | News | Coronavirus plays - vaccines, drugs & infection control products | N/A | |
| 2020-04-23 20:12 EST | News | Familiar names gain as COVID-19 weighs on market | N/A | |
| 2020-04-23 20:10 EST | News | Coronavirus plays on the move premarket | N/A | |
| 2020-04-11 08:54 EST | News | Tiny firms riding coronavirus wave | N/A | |
| 2020-04-11 08:17 EST | News | China Pharma reports FY results | N/A | |
| 2020-04-07 12:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 00:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-01 16:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-31 21:38 EST | News | China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript | N/A | |
| 2020-02-28 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 23:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-14 23:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 23:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 03:31 EST | Earnings | Earnings have been released on September 30, 2011, with $0.08 earnings per share. | Sell | |
| 2020-01-28 03:31 EST | Earnings | Earnings have been released on June 30, 2011, with $0.12 earnings per share. | Buy | |
| 2020-01-28 03:31 EST | Earnings | Earnings have been released on December 31, 2010, with $0.15 earnings per share. | Sell | |
| 2020-01-27 23:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-15 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-21 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-16 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-27 23:24 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-26 23:24 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-22 23:22 EST | Financials | Company financials have been released. | Neutral | |
About China Pharma Holdings, Inc (CPHI):
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
General
- Name China Pharma Holdings, Inc
- Symbol CPHI
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 228
- Last Split Factor1000:21804
- Last Split Date2003-08-15
- Fiscal Year EndDecember
- IPO Date2002-04-17
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.chinapharmaholdings.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 3.65
- Price/Book (Most Recent Quarter) 5.34
- Enterprise Value Revenue 4.25
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -186%
- Operating Margin -29%
- Return on Assets -6%
- Return on Equity -116%
- Revenue 10.98 million
- Earnings Per Share -$0.25
- Revenue Per Share $0.25
- Gross Profit 1.48 million
- Quarterly Earnings Growth 1%
View More
Highlights
- Market Capitalization 44.15 million
- EBITDA 257212
- Analyst Target Price $3
- Book Value Per Share $0.18
View More
Share Statistics
- Shares Outstanding 45.58 million
- Shares Float 20.98 million
- % Held by Insiders 4966%
- % Held by Institutions 2.98%
- Shares Short 200138
- Shares Short Prior Month 116202
- Short Ratio 0.08
- Short % of Float 1%
View More
Technicals
- Beta 0.25
- 52 Week High $1.31
- 52 Week Low $0.32
- 50 Day Moving Average 0.94
- 200 Day Moving Average 0.58
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
China Pharma Holdings, Inc (CPHI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
China Pharma Holdings, Inc (CPHI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-13 | $N/A | -$0.02 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.02 | ||
| 2020-03-31 | 2020-06-30 | $1.76 million | $0.00 | ||
| 2019-12-31 | 2020-03-31 | $N/A | -$0.02 | ||
| 2019-09-30 | 2019-12-31 | $2.38 million | -$0.43 | ||
| 2019-06-30 | 2019-09-30 | $2.57 million | -$0.02 | ||
| 2019-03-31 | 2019-06-30 | $2.93 million | -$0.02 | ||
| 2018-12-31 | 2019-03-31 | $3.24 million | -$0.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $2.3 million | -$0.17 | ||
| 2018-06-30 | 2018-09-30 | $3.17 million | -$0.04 | ||
| 2018-03-31 | 2018-06-30 | $3.62 million | -$0.02 | ||
| 2017-12-31 | 2018-03-31 | $3.85 million | -$0.01 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $3.16 million | -$0.32 | ||
| 2017-06-30 | 2017-09-30 | $2.92 million | -$0.05 | ||
| 2017-03-31 | 2017-06-30 | $3.29 million | -$0.05 | ||
| 2016-12-31 | 2017-03-31 | $5.26 million | -$0.02 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $3.13 million | -$0.08 | ||
| 2016-06-30 | 2016-09-30 | $3.54 million | -$0.04 | ||
| 2016-03-31 | 2016-06-30 | $3.64 million | -$0.06 | ||
| 2015-12-31 | 2016-03-31 | $4.5 million | -$0.04 | $0.00 | |
| 2015-09-30 | 2015-12-31 | $4.48 million | -$0.14 | ||
| 2015-06-30 | 2015-09-30 | $5.67 million | $0.07 | ||
| 2015-03-31 | 2015-06-30 | $5.7 million | -$0.09 | ||
| 2014-12-31 | 2015-03-31 | $3.33 million | -$0.19 | $0.00 | |
| 2014-09-30 | 2014-12-31 | $5.57 million | -$0.51 | ||
| 2014-06-30 | 2014-09-30 | $6.13 million | -$0.15 | ||
| 2014-03-31 | 2014-06-30 | $7.11 million | -$0.20 | ||
| 2013-12-31 | 2014-03-31 | $8.42 million | -$0.05 | ||
| 2013-09-30 | 2013-12-31 | $8.12 million | -$0.24 | ||
| 2013-06-30 | 2013-09-30 | $8.03 million | -$0.05 | ||
| 2013-03-31 | 2013-06-30 | $8.27 million | -$0.10 | ||
| 2012-12-31 | 2013-03-31 | $11.65 million | -$0.06 | ||
| 2012-09-30 | 2012-12-31 | $12.18 million | -$0.03 | ||
| 2012-06-30 | 2012-09-30 | $14.6 million | $0.03 | ||
| 2012-03-31 | 2012-06-30 | $16.09 million | $0.04 | ||
| 2011-12-31 | 2012-03-31 | $22.46 million | $0.06 | ||
| 2011-09-30 | 2011-12-31 | $20.99 million | $0.09 | $0.12 | -25% |
| 2011-06-30 | 2011-09-30 | $19.6 million | $0.11 | $0.11 | 0% |
| 2011-03-31 | 2011-06-30 | $18.12 million | $0.12 | $0.12 | -2.75% |
| 2010-12-31 | 2011-03-31 | $23.97 million | $0.12 | $0.16 | -26.5% |
| 2010-09-30 | 2010-12-31 | $18.68 million | $0.15 | $0.13 | 15.38% |
| 2010-06-30 | 2010-08-10 | $16.63 million | $0.12 | $0.11 | 9.09% |
| 2010-03-31 | 2010-05-11 | $15.1 million | $0.10 | $0.11 | -9.09% |
| 2009-12-31 | 2010-03-05 | $19.58 million | $0.12 | $0.14 | -14.29% |
| 2009-09-30 | 2009-11-11 | $15.52 million | $0.17 | $0.12 | 41.67% |
| 2009-06-30 | 2009-08-11 | $13.6 million | $0.10 | $0.10 | 0% |
| 2009-03-31 | 2009-05-15 | $12.99 million | $0.09 | $0.13 | -30.77% |
| 2008-12-31 | 2009-03-17 | $15.36 million | $0.13 | $0.11 | 18.18% |
| 2008-09-30 | 2008-11-07 | $12.61 million | $0.10 | $0.09 | 11.11% |
| 2008-06-30 | 2008-08-06 | $11.28 million | $0.10 | $0.11 | -9.09% |
| 2008-03-31 | 2008-05-02 | $11.72 million | $0.11 | ||
| 2007-09-30 | 2007-11-15 | $8.29 million | $0.08 | ||
| 2007-06-30 | 2007-08-14 | $8.57 million | $0.09 | ||
| 2007-03-31 | 2007-05-15 | $7.23 million | $0.07 | ||
| 2006-12-31 | 2006-12-31 | $0.10 | |||
| 2006-09-30 | 2006-11-14 | $0.05 | $0.05 | 0% | |
| 2006-06-30 | 2006-06-30 | $0.05 | |||
| 2006-03-31 | 2006-03-31 | $0.05 | |||
| 2005-06-30 | 2005-06-30 | -$2.09 | |||
| 2005-03-31 | 2005-03-31 | -$0.06 | |||
| 2004-12-31 | 2004-12-31 | -$0.03 | |||
| 2004-09-30 | 2004-09-30 | -$0.02 | |||
| 2004-06-30 | 2004-06-30 | -$0.16 | |||
| 2004-03-31 | 2004-03-31 | $0.01 | |||
| 2003-12-31 | 2003-12-31 | $-0.00 | |||
| 2003-09-30 | 2003-09-30 | -$0.89 | |||
| 2003-06-30 | 2003-06-30 | -$0.04 | |||
| 2003-03-31 | 2003-03-31 | -$0.25 | |||
| 2002-12-31 | 2002-12-31 | -$0.32 | |||
| 2002-09-30 | 2002-09-30 | $0.00 | |||
| 2002-06-30 | 2002-06-30 | -$1.68 |
China Pharma Holdings, Inc (CPHI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | 48819 | N/A | 39716 |
| Income Before Tax | N/A | N/A | -660897 | N/A | -700954 |
| Selling General Administrative | N/A | N/A | 714654 | N/A | 946943 |
| Gross Profit | N/A | N/A | 194439 | N/A | 372759 |
| Ebit | N/A | N/A | 57027 | N/A | -645204 |
| Operating Income | N/A | N/A | -569034 | N/A | -645204 |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | 1.76 million | N/A | 2.38 million |
| Cost of Revenue | N/A | N/A | 1.57 million | N/A | 2 million |
| Total Other Income Expense Net | N/A | N/A | -30246 | N/A | -55750 |
| Net Income From Continuing Operations | N/A | N/A | -660897 | N/A | -700954 |
| Net Income Applicable to Common Shares | -1.01 million | 13053 | N/A | -18.75 million | -700954 |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -347795 | N/A | N/A |
| Change to Liabilities | -52273 | -1.28 million | N/A | -965395 | -137138 |
| Total Cash Flow from Investing Activities | -259429 | -492654 | N/A | -50264 | -12201 |
| Net Borrowings | -1.23 million | 1.98 million | N/A | -4986 | -1.35 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -106993 | N/A | -1.35 million |
| Change to Operating Activities | -386823 | -342138 | N/A | 634617 | 192005 |
| Change in Cash | N/A | N/A | -707917 | N/A | -894286 |
| Total Cash from Operating Activities | -224388 | 91415 | -244155 | -795366 | 471878 |
| Depreciation | N/A | N/A | 655921 | N/A | 685930 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | -24688 | N/A | 483567 |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -123607 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 17386 | -5318 | N/A | 17.13 million | 5122 |
| Capital Expenditures | N/A | N/A | 347795 | N/A | 12201 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 14.06 million | N/A | 12.54 million |
| Total Stockholder Equity | N/A | N/A | 8.38 million | N/A | 27.36 million |
| Other Current Liabilities | 6.3 million | N/A | N/A | N/A | 5.61 million |
| Total Assets | N/A | N/A | 22.44 million | N/A | 39.9 million |
| Common Stock | 43580 | 43580 | N/A | 43580 | 43580 |
| Other Current Assets | 38465 | N/A | N/A | N/A | 492141 |
| Retained Earnings | -27.63 million | -26.62 million | -26.63 million | -25.97 million | -7.23 million |
| Other Liabilities | 771820 | 742450 | N/A | 753444 | 743143 |
| Other Assets | N/A | N/A | N/A | N/A | 16.6 million |
| Cash | N/A | N/A | 145932 | N/A | 761606 |
| Total Current Liabilities | 11.55 million | N/A | 11.17 million | N/A | 9.61 million |
| Other Stockholder Equity | 11.86 million | 11.38 million | N/A | 11.58 million | 10.95 million |
| Property, Plant & Equipment | 15.91 million | 15.72 million | N/A | 16.45 million | 16.85 million |
| Total Current Assets | 5.03 million | N/A | 6.36 million | N/A | 6.24 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 7.68 million | 8.21 million | N/A | 9.03 million | 27.15 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | 2.12 million | N/A | 2.12 million |
| Inventory | 3.62 million | N/A | 3.63 million | N/A | 3.97 million |
| Accounts Payable | 989641 | N/A | 847760 | N/A | 1.16 million |
China Pharma Holdings, Inc (CPHI) Chart:
China Pharma Holdings, Inc (CPHI) News:
Below you will find a list of latest news for China Pharma Holdings, Inc (CPHI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
China Pharma Holdings, Inc (CPHI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest CPHI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:04 PM EST | 1000 | $0.245 |
| Jun 13, 2022 7:04 PM EST | 400 | $0.245 |
China Pharma Holdings, Inc (CPHI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/0001213900-20-012258-index.htm |
| 2012-03-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1106644/000000000012011860/0000000000-12-011860-index.htm |
| 2012-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1106644/000091957412001550/0000919574-12-001550-index.htm |
| 2013-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1106644/000091957413000765/0000919574-13-000765-index.htm |
| 2012-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1106644/000093739412000076/0000937394-12-000076-index.htm |
| 2012-02-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000139/0001010549-12-000139-index.htm |
| 2012-02-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000205/0001010549-12-000205-index.htm |
| 2012-03-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000215/0001010549-12-000215-index.htm |
| 2012-03-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000232/0001010549-12-000232-index.htm |
| 2012-03-06 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000234/0001010549-12-000234-index.htm |
| 2012-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000255/0001010549-12-000255-index.htm |
| 2012-04-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000438/0001010549-12-000438-index.htm |
| 2012-05-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000445/0001010549-12-000445-index.htm |
| 2012-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000533/0001010549-12-000533-index.htm |
| 2012-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000896/0001010549-12-000896-index.htm |
| 2012-11-09 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054912001175/0001010549-12-001175-index.htm |
| 2012-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054912001213/0001010549-12-001213-index.htm |
| 2012-11-19 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054912001246/0001010549-12-001246-index.htm |
| 2012-12-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054912001324/0001010549-12-001324-index.htm |
| 2013-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000005/0001010549-13-000005-index.htm |
| 2013-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000144/0001010549-13-000144-index.htm |
| 2013-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000329/0001010549-13-000329-index.htm |
| 2013-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000521/0001010549-13-000521-index.htm |
| 2013-09-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000560/0001010549-13-000560-index.htm |
| 2013-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000594/0001010549-13-000594-index.htm |
| 2013-11-06 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000624/0001010549-13-000624-index.htm |
| 2013-11-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000626/0001010549-13-000626-index.htm |
| 2013-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000676/0001010549-13-000676-index.htm |
| 2013-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054913000745/0001010549-13-000745-index.htm |
| 2014-03-20 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000114/0001010549-14-000114-index.htm |
| 2014-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000242/0001010549-14-000242-index.htm |
| 2014-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000422/0001010549-14-000422-index.htm |
| 2014-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000619/0001010549-14-000619-index.htm |
| 2014-11-20 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000633/0001010549-14-000633-index.htm |
| 2014-11-21 | DEFA14C | Additional information statement materials, definitive | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000635/0001010549-14-000635-index.htm |
| 2014-12-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054914000673/0001010549-14-000673-index.htm |
| 2015-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000090/0001010549-15-000090-index.htm |
| 2015-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000168/0001010549-15-000168-index.htm |
| 2015-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000256/0001010549-15-000256-index.htm |
| 2015-10-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000313/0001010549-15-000313-index.htm |
| 2015-10-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000314/0001010549-15-000314-index.htm |
| 2015-11-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000343/0001010549-15-000343-index.htm |
| 2015-12-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000387/0001010549-15-000387-index.htm |
| 2015-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000389/0001010549-15-000389-index.htm |
| 2015-12-28 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000416/0001010549-15-000416-index.htm |
| 2015-12-28 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000418/0001010549-15-000418-index.htm |
| 2015-12-28 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000420/0001010549-15-000420-index.htm |
| 2015-12-28 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054915000422/0001010549-15-000422-index.htm |
| 2016-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000541/0001010549-16-000541-index.htm |
| 2016-05-16 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000606/0001010549-16-000606-index.htm |
| 2016-08-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000678/0001010549-16-000678-index.htm |
| 2016-10-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000755/0001010549-16-000755-index.htm |
| 2016-10-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000757/0001010549-16-000757-index.htm |
| 2016-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000787/0001010549-16-000787-index.htm |
| 2016-12-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000834/0001010549-16-000834-index.htm |
| 2016-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000864/0001010549-16-000864-index.htm |
| 2016-12-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000101054916000877/0001010549-16-000877-index.htm |
| 2017-03-31 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000101054917000112/0001010549-17-000112-index.htm |
| 2017-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000101054917000167/0001010549-17-000167-index.htm |
| 2012-02-15 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1106644/000116613412000005/0001166134-12-000005-index.htm |
| 2013-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1106644/000116613413000006/0001166134-13-000006-index.htm |
| 2017-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390017003047/0001213900-17-003047-index.htm |
| 2017-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390017008653/0001213900-17-008653-index.htm |
| 2017-09-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390017009599/0001213900-17-009599-index.htm |
| 2017-11-03 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000121390017011352/0001213900-17-011352-index.htm |
| 2017-11-03 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000121390017011354/0001213900-17-011354-index.htm |
| 2017-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390017012067/0001213900-17-012067-index.htm |
| 2017-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390017013370/0001213900-17-013370-index.htm |
| 2018-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390018002824/0001213900-18-002824-index.htm |
| 2018-04-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000121390018003895/0001213900-18-003895-index.htm |
| 2018-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390018006100/0001213900-18-006100-index.htm |
| 2018-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390018010992/0001213900-18-010992-index.htm |
| 2018-10-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000121390018014459/0001213900-18-014459-index.htm |
| 2018-10-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000121390018014461/0001213900-18-014461-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390018015783/0001213900-18-015783-index.htm |
| 2018-12-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390018017006/0001213900-18-017006-index.htm |
| 2019-03-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000121390019005094/0001213900-19-005094-index.htm |
| 2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390019008566/0001213900-19-008566-index.htm |
| 2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390019015792/0001213900-19-015792-index.htm |
| 2019-11-06 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1106644/000121390019022241/0001213900-19-022241-index.htm |
| 2019-11-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1106644/000121390019022243/0001213900-19-022243-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390019023467/0001213900-19-023467-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1106644/000121390019026825/0001213900-19-026825-index.htm |
| 2020-03-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/0001213900-20-008020-index.htm |
| 2020-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/0001213900-20-012258-index.htm |
| 2020-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1106644/000121390020021867/0001213900-20-021867-index.htm |
China Pharma Holdings, Inc (CPHI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of China Pharma Holdings, Inc (CPHI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 4966%Institutional Ownership: 298%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2012-04-28 | FRANK WAUNG | Chief Financial Officer | Buy | 100,000.00 | 138,415.00 | https://www.sec.gov/Archives/edgar/data/1106644/000101054912000445/0001010549-12-000445-index.htm |